Chapter 5
The Role of Atypical Antipsychotics in Inadequate-response and Treatment-resistant Depression
Siegfried Kasper,
Elena Akimova,
Siegfried Kasper
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorElena Akimova
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorSiegfried Kasper,
Elena Akimova,
Siegfried Kasper
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorElena Akimova
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorSiegfried Kasper MD,
Stuart Montgomery MD,
Siegfried Kasper MD
Professor and Chair, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna Austria
Search for more papers by this authorStuart Montgomery MD
Emeritus Professor of Psychiatry Professor of Psychiatry (retired), Imperial College of Science, Technology and Medicine, University of London, London UK
Search for more papers by this authorBook Author(s):Siegfried Kasper MD,
Stuart Montgomery MD,
Siegfried Kasper MD
Professor and Chair, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna Austria
Search for more papers by this authorStuart Montgomery MD
Emeritus Professor of Psychiatry Professor of Psychiatry (retired), Imperial College of Science, Technology and Medicine, University of London, London UK
Search for more papers by this authorSummary
Atypical antipsychotics, or second-generation antipsychotics (SGAs) as they are also called, have been introduced for the treatment of schizophrenia and, subsequently, for bipolar disorder. Substantial research on the combination therapy of antidepressants and SGAs has revealed that they are a valuable addition to antidepressant therapy. As a result of these studies, quetiapine has been approved in Europe as an add-on medication to ongoing antidepressant treatment in patients with a suboptimal response to antidepressants. In the USA, aripiprazole has also been granted indication for the adjunctive treatment of major depression, and olanzapin has the indication for combination with fluoxetine in treatment-resistant depression (TRD). Although a number of questions remain, it is apparent that the appropriate use of SGAs is a promising option for treatment in depression. In this chapter, the clinical evidence in everyday practice as well as the efficacy and side effects are described in detail.
References
- Bauer, M., Pretorius, H. W., Constant, E. L. et al. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with majore depressive disorder: results of a randomized, placebo-controlled, double-blind study. J. Clin. Psychiatry, 70, 540–549.
- Bauer, M., Bschor, T., Pfennig, A. et al. on behalf of the WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry, 8, 67–104.
- Berman, R. B., Fava, M., Thase, M. E. et al. (2008) The third consecutive, positive, double-blind, placebo controlled trial of aripiprazole augmentation in the treatment of major depression. American College of Neuropsychopharmacology 2008 Annual Meeting Abstracts (Scottsdale, AZ, December 7–11, 2008), ACNP, Nashville, TN, USA.
- Berman, R. M., Marcus, R. N., Swanink, R. et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 68, 843–853.
- Blier, P., Ward, H. E., Tremblay, P. et al. (2010) Combination of antidepressant medications from treatment. initiation for major depressive disorder: a double-blind randomized study. Am. J. Psychiatry, 167, 281–288.
- Chen, J., Gao, K. & Kemp, D. E. (2011) Second-generation antipsychotics in major depressive disorder? Update and clinical perspective. Curr. Opin. Psychiatry, 24, 10–17.
- Correll, C. U., Leucht, S. & Kane, J. M. (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry, 161, 414–425.
- Corya, S. A., Williamson, D. J., Sanger, T. M. et al. (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression & Anxiety, 23, 364–372.
- Dunner, D. L., Amsterdam, J. D., Shelton, R. C. et al. (2007) Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry, 68, 1071–1077.
- Earley, W., McIntyre, A., Bauer, M. et al. (2007) Efficacy and tolerability of extended release quetiapine fumarate (quetiapine extended release) as add-on to antidepressants in patients with major depressive disorder (MDD): results from a double-blind, randomized, phase III study. American College of Neuropsychopharmacology 2007 Annual Meeting Abstracts (Boca Raton, FL, December 9–13, 2007), ACNP, Nashville, TN, USA.
- El-Khalili, N., Joyce, M., Atkinson, S. et al. (2008) Adjunctive extended-release quetiapine fumarate (quetiapine-extended release) in patients with major depressive disorder and inadequate antidepressant response. American Psychiatric Association 2008 Annual Meeting: New Research Abstracts (Washington, DC, May 3–8, 2008), APA, Washington, DC, USA.
- El-Khalili, N., Joyce, M., Atkinson, S. et al. (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol., 13, 917–932.
- European Medicines Agency (2011) Seroquel XR. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Seroquel_XR/human_referral_000206.jsp&mid=WC0b01ac0580024e9a, last accessed November 9, 2012.
- Farah, A. (2005) Atypicality of atypical antipsychotics. Prim. Care Comp., 7, 268–274.
- Fava, M. (2001) Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry, 62(Suppl.), 4–11.
- Fava, M., Wisniewski, S. R., Thase, M. E. et al. (2009) Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J. Clin. Psychopharmacol., 29, 362–367.
- Goodwin, G., Fleischhacker, W., Arango, C. et al. (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur. Neuropsychopharmacol., 19, 520–532.
- Grohmann, R., Engel, R. R., Rüther, E. & Hippius, H. (2004) The AMSP Drug Safety Program: methods and global results. Pharmacopsychiatry, 37(Suppl.), 4–11.
- Hartung, D. M., Wisdom, J. P., Pollack, D. A. et al. (2008) Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J. Clin. Psychiatry, 69, 1540–1547.
- Jensen, N. H., Rodriguiz, R. M., Caron, M. G. et al. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacol., 33, 2303–2312.
- Kasper, S. (1998) How much do novel antipsychotics benefit the patients? Int. Clin. Psychopharmacol., 13(Suppl.), 71–77.
- Kasper, S., Lowry, A., Hodge, A. et al. (2006) Tardive dyskinesia: analysis of outpatients with schizophrenia from Latin America, Asia, Central and Eastern Europe, and Africa and the Middle East. Schiz. Res., 81, 139–143.
- Kaye, J. A., Bradbury, B. D. & Jick, H. (2003) Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000, a population-based observational study. Brit. J. Clin. Pharmacol., 56, 569–575.
- Keitner, G. I., Garlow, S. J., Ryan, C. E. et al. (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J. Psy. Res., 43, 205–214.
- Khullar, A., Chokka, P., Fullerton, D. et al. (2006) A double-blind, randomized, placebo-controlled study of quetiapine as augmentation therapy to SSRI/SNRI agents in the treatment of non-psychotic unipolar depression with residual symptoms. American Psychiatric Association 2006 Annual Meeting: New Research Abstracts (Toronto, Canada, May 20–25, 2006), APA Washington, DC, USA.
- Klein, N., Sacher, J., Wallner, H. et al. (2004) Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. CNS Spectrum, 9, 823–832.
- Konstantinidis, A., Hrubos, W., Nirnberger, G. et al. (2007) Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 242–247.
- Konstantinidis, A., Papageorgiou, K., Grohmann, R. et al. (2012) Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int. J. Neuropsychopharmacol., 15, 449–457.
- Lenderts, S. & Kalali, A. (2009) Treatment of depression: an update on antidepressant monotherapy and combination therapy. Psychiatry, 6, 15–17.
- Liebowitz, M., Lam, R. W., Lepola, U. et al. (2010) Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depression & Anxiety, 27, 964–976.
- Mahmoud, R. A., Pandina, G., Turkoz, I. et al. (2007) Risperidone for treatment-refractory major depressive disorder. Ann. Int. Med., 147, 593–602.
- Marcus, R., McQuade, R., Carson, W. et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind placebo-controlled study. J. Clin. Psychopharmacol., 28, 156–165.
- Mattingly, G., Ilivicky, H., Canale, J. & Anderson, R. (2006) Quetiapine combination for treatment-resistant depression. American Psychiatric Association 2006 Annual Meeting: New Research Abstracts (Toronto, Canada, May 20–25, 2006), APA, Washington, DC, USA.
- McIntyre, A., Gendron, A. & McIntyre, A. (2007) Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depression & Anxiety, 24, 487–494.
- Mohamed, S., Leslie, D. L. & Rosenheck, R. A. (2009) Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. J. Clin. Psychiatry, 70, 906–912.
- Nelson, J. C. (1987) The use of antipsychotic drugs in the treatment of depression, in Treating Resistant Depression (ed. J. Zohar & R. H. Belmaker), PMA Publishing, New York, NY, pp. 131–146.
- Nelson, J. C. & Papakostas, G. I. (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry, 166, 980–991.
- Olfson, M. & Marcus, S. C. (2009) National patterns in antidepressant medication treatment. Arch. Gen. Psychiatry, 66, 848–856.
- Ostroff, R. B. & Nelson, J. C. (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry, 60, 256–259.
- Papakostas, G. I., Shelton, R. C., Smith, J. & Fava, M. (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry, 68, 826–831.
- Philip, N. S., Carpenter, L. L., Tyrka, A. R. & Price, L. H. (2008) Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J. Psy. Pract., 14, 34–44.
- Philip, N. S., Carpenter, L. L., Tyrka, A. R. & Price, L. H. (2010) Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Exp. Op. Pharacother., 11, 709–722.
- Reeves, H., Batra, S., May, R. S. et al. (2008) Efficacy of risperidone augmentation to antidepressant in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo controlled pilot study. J. Clin. Psychiatry, 69, 1228–1336.
- Reynolds, G. P. (2004) Receptor mechanisms in the treatment of schizophrenia. J. Psychopharmacol., 18, 340–345.
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R. et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am. J. Psychiatry, 163, 1905–1917.
- Schläpfer, T., Agren, H., Monteleone, P. et al. (2012) The hidden third: improving outcome in treatment resistant depression. J. Psychopharmacol., 26, 587–602.
- Shelton, R. C. & Papakostas, G. I. (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr. Scand., 117, 253–259.
- Shelton, R. C., Tollefson, G. D., Tohen, M. et al. (2001) A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry, 158, 131–134.
- Shelton, R. C., Williamson, D. J., Corya, S. A. et al. (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry, 66, 1289–1297.
- Stahl, M. (2000) Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Cambridge University Press, Cambridge, UK.
- Stahl, S. M. & Shayegan, D. K. (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry, 64(Suppl. 19), 6–12.
- Tadori, Y., Forbes, R. A., McQuade, R. D. & Kikuchi, T. (2008) Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur. J. Pharmacol., 597, 27–33.
- Tatsumi, M., Jansen, K., Blakely, R. D. & Richelson, E. (1999) Pharmacologic profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol., 368, 277–283.
- Thase, M., Corya, S. A., Osuntokun, O. et al. (2007) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry, 68, 224–236.
- Wheeler Vega, J. A., Mortimer, A. M. & Tyson, P. J. (2003) Conventional antipsychotic prescription in unipolar depression, I: an audit and recommendations for practice. J. Clin. Psychiatry, 64, 568–574.
- Zhang, W., Perry, K. W., Wong, D. T. et al. (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacol., 23, 250–262.
